Table 2.
Summary of published studies on endoscopic ampullectomy
| Study | Year | Patients (N) | Success N (%) | Histology | Complications (%) | Recurrence N (%) | Surgery N (%) | Mortality |
|---|---|---|---|---|---|---|---|---|
| Binmoeller (17) | 1993 | 25 | 23 (92%) | 25 adenomas (18 MGD, 1 HGD) | Pancreatitis (12%) Bleeding (8%) |
6 (26%) | 3 (12%) | 0 |
| Vogt (18) | 2000 | 18 | 12 (67%) | 18 adenomas | Pancreatitis (11%) Bleeding (11%) Stent occlusion (6%) |
6 (33%) | 3 (17%) | |
| Park (19) | 2000 | 6 | 5 (83%) | 4 adenomas 2 carcinomas |
Pancreatitis (33%) | 0 | 1 (17%) | |
| Zadorova (20) | 2001 | 16 | 13 (81%) | 16 adenomas | Pancreatitis (13%) Bleeding (13%) |
3 (19%) | 1 (6%) | |
| Desilets (21) | 2001 | 13 | 12 (92%) | 13 adenomas (1 HGD) | Pancreatitis (8%) | 0 | 1 (8%) | |
| Norton (22) | 2002 | 26 | 26 (100%) | 25 adenoma 1 carcinoma 1 inflammatory polyp 1 normal papilla |
Bleeding (8%) Acute pancreatitis (15%) Pancreatitis due to PD stenosis (8%) Perforation (4%) |
2(10%) | 1 (4%) | |
| Cheng (23) | 2004 | 55 | 39 (74%) | 45 adenoma (7 HGD) 5 carcinoma 2 carcinoid 1 gastric heterotopia 2 normal histology |
Pancreatitis (9%) Bleeding (7%) Perforation (2%) |
9 (16%) | 7 (13%) | |
| Catalano (24) | 2004 | 103 | 83 (80%) | 97 adenoma (14 HGD) 6 carcinoma |
Pancreatitis (5%) Papillary stenosis (3%) Bleeding (2%) |
20 (20%) | 16 (16%) | |
| Moon (25) | 2005 | 6 | 6 (100%) | 6 adenoma | Pancreatitis (17%) Cholangitis (17%) |
0 | 0 | |
| Han (26) | 2005 | 22 | 16 (73%) | 14 adenoma (3 HGD) 2 adenocarcinoma 1 carcinoid 3 chronic inflammation 1 adenomatous hyperplasia 1 cavernous lymphangioma |
Bleeding (18%) Papillary stenosis (% 5) Perforation (%5) Cholangitis (%5) Abnormal LTs (%5) |
1 (4.5%) | 0 | 0 |
| Bohnaker (27) | 2005 | 106 | 73 (73%) | 92 adenoma (18 HGD) 4 carcinoma 1 lymphangioma 12 hyperplastic |
Bleeding (13%) Pancreatitis (6%) |
15 (15%) | 19 (19%) | |
| Harewood (28) | 2005 | 19 | NR | NR | Pancreatitis (16%) Cholangitis (5%) Abdominal pain (5%) |
NR | NR | |
| Katsinelos (29) | 2006 | 14 | 11 (79%) | 11 adenoma 3 carcinoma |
Pancreatitis (7%) Bleeding (7%) |
2 (18%) | 3 (21%) | |
| Boix (30) | 2008 | 21 | 6 (28.5%) | 11 adenoma (4 HGD) 10 carcinoma |
Pancreatitis (19%) Bleeding (5%) |
1 (16.6%) | 15 (71.4%) | |
|
| ||||||||
| Jung (31) | 2008 | 22 | 12 (55%) | 11 adenoma (2 HGD) 9 carcinoma 1 lymphoma 1 inflammation |
Pancreatitis (18%) Bleeding (5%) Perforation (5%) |
2 (16.7%) | 6 (27%) | |
| Irani (32) | 2009 | 102 | 86 (84%) | 94 adenoma 8 carcinoma |
Pancreatitis (10%) Bleeding (5%) Perforation (2%) Cholangitis (1%) Papillary stenosis (3%) |
8 (8%) | 16 (16%) | |
| Yamao (33) | 2010 | 36 | 29 (81%) | 26 adenoma 8 carcinoma 1 hyperplastic 1 inflammation |
Pancreatitis (8%) Bleeding (8%) Biliary stenosis (3%) |
1 (3%) | 1 (3%) | |
| Malet (34) | 2011 | 42 | 39 (93%) | 30 adenoma (10 HGD and CIS) 7 inflammatory 2 somatostatinoma |
Pancreatitis (14%) Bleeding (7%) Cholangitis (2%) |
4 (10%) | 4 (%10) | |
| Patel (35) | 2011 | 38 | 38 (100%) | 38 adenoma (6 HGD) | Pancreatitis (8%) Bleeding (5%) Infection (3%) |
6 (16%) | 0 | |
| Salmi (36) | 2012 | 61 | 56 (82%) | 33 adenoma (11 HGD) 10 adenocarcinoma 3 endocrine carcinoma 16 no dysplasia |
Pancreatitis (10%) Bleeding (5%) Perforation (3%) |
3 (5 %) | 5 (8%) | |
| Laleman (37) | 2013 | 91 | 71 (78%) | 65 adenoma (19 HGD) 16 carcinoma 12 non-specific |
Pancreatitis (15%) Bleeding (12%) Cholangitis (4%) |
13 (18%) | 14 (15%) | |
| Napoleon (38) | 2014 | 93 | 84 (90 %) | 66 adenoma (32 HGD) 13 carcinoma 7 Inflammation 3 Adenomyomatosis 3 Brunner gland 1 neuroendocrine tumor |
Pancreatitis (20%) Bleeding (10%) Perforation (3.6%) Biliary (7 %) Papillary stenosis (1.8%) |
5 (5.3%) | 5 (5.3%) | 1 |
| De Palma (39) | 2015 | 27 | 25 (93%) | 22 adenoma (4 HGD) 3 adenocarcinoma |
Pancreatitis (11%) Bleeding (7%) |
1 (4%) | 2 (7%) | |
| Tsuji (40) | 2015 | 115 | 113 (98.2%) | 85 adenoma 13 cancer in adenoma 10 cancer 7 hyperplasia |
Pancreatitis (10.2 %) Bleeding (18 %) Perforation (2.6%) Cholangitis (1.7%) Papillary stenosis (4.3%) |
NR | 1 (0.9%) | 1 |
| Current Study | 44 | 40 (91%) | 18 adenoma (4 HGD) 9 adenocarcinoma 7 tubullovillous adenoma 5 tubullovillous adenoma with mucosal carcinoma 1 neuroendocrine tumor 1 ganglioneuroma 1 hamartomatous polyp 1 adenofibroma 1 Brunner gland hyperplasia |
Bleeding (6.8%) Pancreatitis (4.5%) Abdominal pain (2.3%) Stent migration (2.3%) |
7 (17%) | 3 (6.8%) | 0 | |
| Total | 1121 | 918 (81.8%) | 872 adenoma (79%) 137 carcinoma (12.3%) 84 non-neoplastic (7.6%) 11 NET (1 %) 1 Lymphoma |
Pancreatitis (10.3%) Bleeding (8.9%) Perforation (1.7%) Stenosis (1.5%) Cholangitis (1%) |
115 (11.6%) | 127 (11.3%) | 2 (% 0.1) | |
MGD: moderate grade dysplasia; HGD: high grade dysplasia; CIS: carcinoma in situ; PD: pancreatic duct; LTs: liver tests; NR: not reported; NET: neuroendocrine tumor